Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System Approved for Marketing in Russia

Moscow, Russia, 4 January 2023 — MicroPort® has recently received registration approval from the Federal Service for Surveillance in Healthcare of Russia for its self-developed Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™).

Firehawk Liberty™ is a drug-eluting stent (DES) featuring strut in-groove coating and precision target drug-releasing patent technology. It combines the advantages of the bare metal stent and drug-eluting stent, with nearly 600 grooves evenly cut in the hair-thin but extremely hard CoCr alloy. It allows for the precise injection of drugs into the micro-grooves by means of a fully automatic 3D-printed micro-groove filling, which contributes to the effectiveness of the drug while significantly reducing the drug loading.

While retaining some features of previous Firehawk Stent, the new Firehawk Liberty™ uses an innovative stent balloon technology to optimize expansion performance, offering better crossability, traceability and pushability, thus further optimizing the crossability and vessel wall apposition.

Firehawk Liberty™ is currently approved in a number of countries and regions including the European Union, Korea, India, Brazil, Colombia, Belarus, Egypt, and Saudi Arabia. So far, MicroPort®'s line of drug-eluting stent products have been approved for use in 38 countries and regions around the world. The introduction of the Firehawk Liberty™ into the Russian market has further expanded MicroPort®'s range of coronary products available in the country. In the future, MicroPort® will continue to introduce more high-quality and innovative medical devices to overseas markets, so as to offer a more thorough medical solution for patients.

About MicroPort®

Founded in Shanghai in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort Scientific Corporation (“MicroPort®”, stock code: 00853.HK) is today a global medical devices company with over 12,000 employees worldwide. We provide solutions across twelve therapeutic areas, including orthopedics, cardiac rhythm management, electrophysiology and endovascular. At MicroPort®, we are breaking barriers and accelerating access to life-changing solutions with the purpose of prolonging and reshaping the lives of patients everywhere. Our therapeutic solutions are available in more than 100 countries and over 20,000 hospitals around the world, and today, a patient benefits from a MicroPort® solution every six seconds.

More information is available at https://microport.com/news.